B. Riley analyst Mayank Mamtani says the firm "came away encouraged from AACR’23" regarding its thesis on Agenus, citing what it calls the a "renaissance of anti CTLA4 as a key immune ‘priming’ target" and "FDA’s bar elevated to allow for accelerated approval." Earlier in the week, Agenus announced receiving Fast Track Designation from the FDA for its combination therapy of botensilimab and balstilimab in patients with non-microsatellite instability-high/deficient mismatch repair non-liver metastatic colorectal cancer, or non-liver-mets MSS-CRC, and the firm contends that the company’s bot-bal combination data in 3L+ MSS CRC, across both non liver met and liver met, "represents best-in-indication data generated to date." The firm reiterates a Buy rating and $8 price target on Agenus shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AGEN:
- Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab
- Agenus announces results from cohort in study of botensilimab with balstilimab
- Agenus announces 2023 catalysts, objectives
- Agenus reports Q4 EPS (24c), consensus (22c)
- Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
Questions or Comments about the article? Write to editor@tipranks.com